Actively Recruiting
Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer
Led by Shanghai Pulmonary Hospital, Shanghai, China · Updated on 2026-01-07
36
Participants Needed
1
Research Sites
47 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a prospective, single-arm, exploratory clinical research aimed at evaluating the efficacy and safety of lucetamab in combination with leucovorin in the conversion therapy of locally advanced potentially resectable EGFR mutation-positive non-small cell lung cancer, providing more robust clinical evidence for the improvement of treatment modalities for EGFR-mutated locally advanced NSCLC. At the same time, it seeks to identify biomarkers that can predict the therapeutic effect of the combination of lucetamab and leucovorin, offering more precise guidance for the selection of clinical treatment plans and enabling patients to receive the optimal treatment regimen.
CONDITIONS
Official Title
Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent form
- Age over 18 years old
- Diagnosed with non-small cell lung cancer with confirmed EGFR mutation by pathology
- Locally advanced NSCLC (stage IIIA, IIIB, or IIIC) confirmed by chest CT, PET-CT, or EBUS, with MDT consensus that immediate surgery is not suitable
- No prior systemic anti-tumor treatment
- At least one measurable lesion according to RECIST 1.1 criteria
- Good lung function and able to tolerate surgery
- ECOG performance status score of 0 to 1
You will not qualify if you...
- Allergy to sacituzumab tirumotecan or any excipients
- Allergy to limertinib or any excipients
- History of other primary tumors or allogeneic organ transplantation
- Major surgery within 4 weeks before first dose (excluding diagnostic biopsy)
- History of drug abuse, long-term alcohol abuse, AIDS, or HIV infection
- Active or past autoimmune diseases that may recur
- Current systemic hormone therapy equivalent to more than 10 mg prednisone daily or other immunosuppressive therapy within 14 days before first dose
- Previous treatment with any EGFR-TKI or TROP2 ADC
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai Pulmonary Hospital
Shanghai, China
Actively Recruiting
Research Team
P
Peng Zhang, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here